EVFM stock information

Sector:

Healthcare

Description:

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Evofem Biosciences, Inc. website

Current Price

$0.02

RSI

34.91

Market Capitalization:

78.8M

Beta:

-0.509

Volume:

3,411,662

Analyst Target Price:

$ 1.88

Economiic Fair Price:

Earnings DateNovember 14, 2022

Report DateAugust 12, 2022

QuarterQ2

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash19.9M

Debt125.7M

EPS-1.752

Profit MarginN/A

Revenue Per Share TTM0.044

Return On Equity TTM-3.873

YoY Revenue Growth (TTM)

762.62 %

YoY Pre Tax Income Growth (TTM)

-105.19 %

YoY Free Cash Flow (TTM)

33.53 %

QoQ Revenue Growth

224.93 %

QoQ Pre Tax Income Growth

-276.97 %

QoQ Free Cash Flow Growth

51.14 %

2021 Revenue

$ 8.2M

1748.43 %

2020 Revenue

$ 446K

2021 Free Cash Flow

$ -149.6M

-39.71 %

2020 Free Cash Flow

$ -107.1M

-93.78 %

2019 Free Cash Flow

$ -55.3M

2.21 %

2018 Free Cash Flow

$ -56.5M

-589.03 %

2017 Free Cash Flow

$ -8.2M

49.55 %

2016 Free Cash Flow

$ -16.3M

2021 Pre Tax Income

$ -205.2M

-44.18 %

2020 Pre Tax Income

$ -142.3M

Evofem Biosciences, Inc.(EVFM)